Gerd Glaeske

Gerd Glaeske

Auto-generated profile, based on publicly available information

Gerd Glaeske

Research Center on Inequality and Social Policy, University of Bremen, Bremen, Germany

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2017 in Child and Adolescent Psychiatry and Mental Health
Verified
Journal Article
Open access
PDF file
LKLuuk J. Kalverdijk
Luuk J. Kalverdijk
CBChristian J Bachmann
Christian J Bachmann
LALise Aagaard
Lise Aagaard
MBMehmet Burcu
Mehmet Burcu
GGGerd Glaeske
Gerd Glaeske
JZJulie Zito
Julie Zito
Over the last decades, an increase in antipsychotic (AP) prescribing and a shift from first-generation antipsychotics (FGA) to second-generation antipsychotics (SGA) among youth have been reported. However, most AP prescriptions for youth are off-label, and there are worrying long-term safety data in youth. The objective of this study was to assess multinational trends in AP use among children and adolescents. A repeated cross-sectional design was applied to cohorts from varied sources from Denmark, Germany, the Netherlands, the United Kingdom (UK) and the United States (US) for calendar years 2005/2006–2012. The annual prevalence of AP use was assessed, stratified by age group, sex and subclass (FGA/SGA). The prevalence of AP use increased from 0.78 to 1.03% in the Netherlands’ data, from 0.26 to 0.48% in the Danish cohort, from 0.23 to 0.32% in the German cohort, and from 0.1 to 0.14% in the UK cohort. In the US cohort, AP use decreased from 0.94 to 0.79%. In the US cohort, nearly all ATP dispensings were for SGA, while among the European cohorts the proportion of SGA dispensings grew to nearly 75% of all AP dispensings. With the exception of the Netherlands, AP use prevalence was highest in 15–19 year-olds. So, from 2005/6 to 2012, AP use prevalence increased in all youth cohorts from European countries and decreased in the US cohort. SGA were favoured in all countries’ cohorts.

1 July 2021 in Clinical Epidemiology
Verified
Journal Article
Open access
KHKristina Hagenström
Kristina Hagenström
KSKristin Sauer
Kristin Sauer
NMNicole Mohr
Nicole Mohr
MDMarleen Dettmann
Marleen Dettmann
GGGerd Glaeske
Gerd Glaeske
MAMatthias Augustin
Matthias Augustin
Information on the prevalence of atopic dermatitis (AD) varies greatly, and so far, only a few studies describe the healthcare of patients with AD in Germany. The aim of the study is to describe the prevalence and medications of people with AD in Germany. Health insurance data for the year 2019 were examined. Prevalence rates, the severity of disease, comorbidities and pharmaceutical supply were analyzed. Insured persons with AD were identified with at least one outpatient or inpatient International Classification Code of Diseases (L20). In 2019, 4.21% [95% CI 4.21−4.22%] of insured persons had AD (3.6 million). Women were affected slightly more frequently than men (4.74% [95% CI 4.73−4.74%] and 3.64% [95% CI 3.64−3.65%]). Adolescents and children under the age of 15 had the highest prevalence of AD compared to other age groups (9.44% [95% CI 9.42−9.46%]). Majority of the insured persons with AD were affected by a mild to moderate form of the disease. The most common co-morbidity was infections of the skin (RR 5.00 [95% CI 4.97−5.02%]). Some patients were treated by a dermatologist, while others by a general practitioner, 39.10% and 36.74%, respectively. Of the anti-inflammatory drugs, systemic glucocorticosteroids preparations were used most frequently and were most frequently prescribed by the general practitioner. With a total of 42,841 prescriptions (1.53%), methotrexate (third-line treatment option) was prescribed more frequently than ciclosporin with 19,628 prescriptions (0.70%) or azathioprine with 25,696 prescriptions (0.92%). Ciclosporin (first-line treatment option) was prescribed much more frequently by a dermatologist (44.00% versus 14.32% by general practitioner). The biological dupilumab was prescribed 30,801 times (1,10%) and was also primarily prescribed by a dermatologist (66.67%). The present results reveal that a specialist treats approximately one-third of the patients with AD and that there is still a drug undersupply in some cases, especially concerning innovative drugs.

1 December 2007 in Das Gesundheitswesen
Verified
Journal Article
Closed access
MPM. S. Pfannkuche
M. S. Pfannkuche
FHFalk Hoffmann
Falk Hoffmann
FMF. Meyer
F. Meyer
GGG. Glaeske
G. Glaeske
Hintergrund: Gesundheitspolitische Diskussionen verfolgen häufig das Ziel, die Effizienz in der Arzneimittelversorgung zu steigern. Hierfür werden Einsparpotenziale quantifiziert, die auf der Grundlage von GKV-Routinedaten basieren. Diese Arbeit versteht sich als Beitrag zur methodischen Diskussion zur Ermittlung solcher Einsparpotenziale. Methodik: Grundlage der Analyse waren Routinedaten der Gmünder ErsatzKasse (GEK) aus dem Jahr 2005. Es werden vier verschiedene Methoden zur Berechnung von Effizienzreserven im Generikamarkt anhand des Wirkstoffs Omeprazol vorgestellt. Ergebnisse: Je nach verwendeter Methodik sind verschiedene Annahmen und Abstraktionen sowie unterschiedliche Informationen erforderlich. Die ermittelten Effizienzreserven differieren in unserem Beispiel zwischen 741 Tsd. Euro und 165 Tsd. Euro (entspricht ca. 80%). Gemessen an den Gesamtausgaben für den Wirkstoff Omeprazol resultieren je nach verwendeter Methodik Einsparpotenziale zwischen 2,9 und 13,1%. Schlussfolgerungen: Die Höhe und auch die Relevanz theoretischer Einsparpotenziale hängen sehr stark von den zugrunde liegenden Annahmen und der verwendeten Methodik ab. Im Idealfall sollten die Berechnungen auf der Ebene des einzelnen Arzneimittels unter Berücksichtigung der Arzneimittelpreise zum Verordnungszeitpunkt erfolgen. Eine ausführliche Beschreibung der Methodik ist Vorraussetzung für eine adäquate Beurteilung der Ergebnisse. Background: Discussions in health-care policy frequently pursue a raising efficiency in drug utilisation. Therefore saving potentials are quantified based on health insurance company claims data. This article is a contribution to methodical discussions about the determination of saving potentials in drug utilisation. Methods: Based on claims data from the health insurance company Gmuender ErsatzKasse (GEK) of 2005, four different methods to calculate efficiency potentials in the generic drug market are presented. The different effects are illustrated for the example of Omeprazol. Results: Depending on the used methods, different estimates, abstractions and varied information are required. In the given example the identified increase in efficiency varies between 741,000 Euro and 165,000 Euro (80%). According to the used method, saving potentials range between 2.9% and 13.1% as measured by the total expenditure for Omeprazol. Conclusion: The amount and the pertinence of saving potentials in theory are highly dependent on underlying assumptions and used methods. Calculations on the level of several drugs should, in the best case, occur at the time of prescription under consideration of drug prices. A detailed methods description is required for an appropriate outcome evaluation.

9 February 2017
Verified
Book Chapter
Closed access
PDF file
GGGerd Glaeske
Gerd Glaeske

20 November 2015 in Der Urologe
Verified
Journal Article
Closed access
PDF file
GGG. Glaeske
G. Glaeske

28 October 2015 in Die Innere Medizin
Verified
Journal Article
Closed access
PDF file
GGG. Glaeske
G. Glaeske